Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

被引：0
|
作者：
Kelley, Robin Kate
Sangro, Bruno
Harris, William Proctor
Ikeda, Masafumi
Okusaka, Takuji
Kang, Yoon-Koo
Qin, Shukui
Tai, Wai Meng David
Lim, Ho Yeong
Yau, Thomas
Yong, Wei-Peng
Cheng, Ann-Lii
Gasbarrini, Antonio
De Braud, Filippo G.
Bruix, Jordi
Borad, Mitesh J.
He, Philip
Negro, Alejandra
Kudo, Masatoshi
Abou-Alfa, Ghassan K.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Clin Univ Navarra, Pamplona, Spain
[3] Biomed Res Networking Ctr Hepat & Digest Dis, Pamplona, Spain
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[6] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[7] Asan Med Ctr, Seoul, South Korea
[8] Jinling Hosp, Canc Ctr, Nanjing, Peoples R China
[9] Natl Canc Ctr Singapore, Singapore, Singapore
[10] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
[11] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China
[12] Natl Univ Canc Inst, Singapore, Singapore
[13] Natl Taiwan Univ Hosp, Taipei, Taiwan
[14] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[15] Univ Cattolica Sacro Cuore, Milan, Italy
[16] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy
[17] Clin & Prov Hosp Barcelona, Barcelona, Spain
[18] Mayo Clin, Canc Ctr, Scottsdale, AZ USA
[19] AstraZeneca, Gaithersburg, MD USA
[20] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[21] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4508
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Rimassa, L.
    Dayyani, F.
    Kelley, R. K.
    Sangro, B.
    Chan, S. L.
    Mccoy, C. L.
    Paskow, M. J.
    Makowsky, M.
    Gupta, C.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
  • [42] Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)
    Hernando Cubero, J.
    Taberna Sanz, M.
    Carmona Bayonas, A.
    Iglesias, L.
    Grande, E.
    Trigo Perez, J. M.
    Grau, J. J.
    Lopez-Picazo, J. M.
    Castelo, B.
    Alonso Gordoa, T.
    Lorenzo, I.
    Casado Herraez, A.
    Ugidos, L.
    Munarriz, J.
    Lavernia, J.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 759 - 759
  • [43] Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) - DUTHY (GETNE-T1812) trial
    Garcia-Alvarez, A.
    Molina-Cerrillo, J.
    Castelo, B.
    Plana, M.
    Iglesias, L.
    Carmona-Bayonas, A.
    Yaya, Tur R.
    Ruiz, S.
    Baste, N.
    Lorenzo-Lorenzo, I
    Alonso-Gordoa, T.
    Capdevila, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 236 - 236
  • [44] Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC)
    Qin, Shukui
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Li, Cindy
    Chen, Wenfeng
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040
    Yau, Thomas
    Zagonel, Vittorina
    Santoro, Armando
    Acosta-Rivera, Mirelis
    Choo, Su Pin
    Matilla, Ana
    He, Aiwu Ruth
    Gracian, Antonio Cubillo
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Eldawy, Tarek
    Bruix, Jordi
    Frassineti, Giovanni
    Vaccaro, Gina M.
    Tschaika, Marina
    Scheffold, Christian
    Shen, Yun
    Neely, Jaclyn
    Piscaglia, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [46] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, L. S.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
  • [47] Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
    Floudas, Charalampos S.
    Xie, Changqing
    Brar, Gagandeep
    Morelli, Maria Pia
    Fioravanti, Suzanne
    Walker, Melissa
    Mabry-Hrones, Donna
    Wood, Brad J.
    Levy, Elliot B.
    Krishnasamy, Venkatesh P.
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [48] Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
    Suzuki, Takanori
    Matsuura, Kentaro
    Sobue, Satoshi
    Kato, Daisuke
    Hayashi, Katsumi
    Kondo, Hiromu
    Anbe, Kaiki
    Mizoshita, Tsutomu
    Okayama, Kohei
    Okumura, Fumihiro
    Kimura, Yoshihide
    Ozasa, Atsushi
    Inada, Hiroki
    Tokunaga, Takayuki
    Narahara, Satoshi
    Kawamura, Hayato
    Fujiwara, Kei
    Nojiri, Shunsuke
    Kataoka, Hiromi
    Tanaka, Yasuhito
    HEPATOLOGY RESEARCH, 2025,
  • [49] Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
    Kelley, Robin Kate
    Sangro, Bruno
    Harris, William
    Ikeda, Masafumi
    Okusaka, Takuji
    Kang, Yoon-Koo
    Qin, Shukui
    Tai, David W-M
    Lim, Ho Yeong
    Yau, Thomas
    Yong, Wei-Peng
    Cheng, Ann-Lii
    Gasbarrini, Antonio
    Damian, Silvia
    Bruix, Jordi
    Borad, Mitesh
    Bendell, Johanna
    Kim, Tae-You
    Standifer, Nathan
    He, Philip
    Makowsky, Mallory
    Negro, Alejandra
    Kudo, Masatoshi
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 2991 - +
  • [50] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466
12345